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Age at menopause marks the end of a woman’s reproductive life and its timing associates with risks for cancer,
cardiovascularand bone disorders. GWAS and candidate gene studies conducted in women of European ances-
try have identified 27 loci associated with age at menopause. The relevance of these loci to women of African an-
cestry has not been previously studied. We therefore sought to uncover additional menopause loci and
investigate the relevance of European menopause loci by performing a GWAS meta-analysis in 6510 women
withAfricanancestry derived from 11studiesacross theUSA. We did not identify any additional loci significantly
associated withageatmenopause inAfricanAmericans.Wereplicated theassociationsbetweensix lociandage
at menopause (P-value < 0.05): AMHR2, RHBLD2, PRIM1, HK3/UMC1, BRSK1/TMEM150B and MCM8. In addition,
associations of 14 loci are directionally consistent with previous reports. We provide evidence that genetic var-
iants influencing reproductive traits identified in European populations are also important in women of African
ancestry residing in USA.
INTRODUCTION
Menopause marks the end of a woman’s reproductive life. It can
occur naturally or be induced. Clinically, natural menopause is
defined as the irreversible cessation of menses for 12 months
with no obvious cause, such as pregnancy or lactation (1–3).
Surgical menopause occurs when both ovaries are removed or
damaged by radiation or chemotherapeutic drugs used in
cancer treatments (3). Age at natural menopause occurs at
50–55 years of age in Caucasian women (1–3). Studies
have shown that the timing of menopause is a risk factor for
osteoporosis, coronary heart disease and cancers. For example,
early menopause is associated with increased mortality from car-
diovascular diseases (4–8). It has been estimated that for every
year’s delay in menopause, the risk for cardiovascular disease is
decreased by 2% (9). Women who suffer from premature meno-
pause, defined as menopause prior to age 40, have a 50% higher
mortality rate than those reporting menopause above age 50
years (4,10,11). To better assist women in their reproductive
decisions and their overall health, it is important to determine
factors influencing the timing of menopause.
Age at natural menopause is a strongly heritable trait, with
more than half of the variation attributed to genetic factors
(10,12). Women were at an increased risk of early or late meno-
pause if their mother or non-twin sister had an early or late meno-
pause (13). The odds ratio of a woman having an early
menopause if their mother had experienced one was 6.02 (1).
Estimates for heritability from mother–daughter and non-twin
sister studies range from 42 to 85% (13,14). Environmental
factors, such as current cigarette smoking, social-economic
status and alcohol consumption, also associate with the onset
of menopause but to a lesser extent (2,3,15,16).
Recent genome-wide association studies (GWAS) in 38 968
women of European ancestry identified numerous single nucleo-
tide polymorphisms (SNPs) associated with age at menopause.
These SNPs clustered 21 loci: RHBDL2, EXO1, FNDC4,
TLK1, METAP1D, HELQ, RNF44, UIMC1/HK3, SYCP2L,
chr13q34, BAT2, ASH2L, FSHB/MPPED2, PRIM1, KPNA3,
TDRD3, POLG, GSPT1, BRSK1/TMEM150B, NLRP11 and
MCM8 (17–19). SNPs in most of these clusters have also been
shown to be associated with early menopause (20,21). Mutations
in genes NOBOX, GDF9, BMP15 and FOXL2 have also been
associated with premature ovarian insufficiency in several can-
didate gene studies (22–26). Most of these genes are implicated
in DNA repair and immune pathways and suggest that ovarian
aging is an early indicator of overall aging (19). Candidate
gene studies in European women have also identified six add-
itional loci associated with age at menopause: F5, CYP1B1,
ESR1, AMHR2, HSDB1 and APOE (27–33).
Epidemiological studies have shown that age at natural
menopause varies across ethnic groups. African and African-
American women were reported to experience menopause at
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least 6–12 months sooner when compared with women of Euro-
pean descent (34–37). To date, however, the majority of the
genetic studies on age at menopause have involved only
women of European ancestry. Genetics studies in various
ethnic groups are especially important in elucidating and distil-
ling the genes controlling the timing of this universal reproduct-
ive event. To extend our understanding of genetic variants
influencing menopause in African-American women, the
Women’s Health Initiative (WHI), the Candidate-gene Associ-
ation Resource (CARe) Consortium, the African American
Breast Cancer Consortium (AABC), the Genetic Epidemiology
Network of Arteriopathy Study (GENOA), the Health Aging and
Body Composition Study (Health ABC), the Healthy Aging in
Neighborhoods of Diversity across the Life Span study
(HANDLS) and the Multi-Ethnic Study of Atherosclerosis
(MESA) Family Study collaborated in this first genome-wide as-
sociation meta-analysis of GWAS on age at menopause in
African-American women. We sought to identify novel loci in-
fluencing the age at menopause in African-American women, to
replicate loci identified in European ancestry populations in
African-American women and to examine the implicated
regions for secondary signals.
RESULTS
Definition of age at natural menopause
Age at natural menopause was defined as the irreversible cessa-
tion of menses for at least 12 months in women who did not
undergo hysterectomy with or without oophorectomy (1,2).
Women with premature menopause, defined as having meno-
pause prior to 40 years of age, and women who reported meno-
pause after 60 years of age were excluded. Women with
hormone use prior to menopause or women who underwent
chemotherapy/radiation were also excluded. The current study
involved women from 11 population-based studies. The detailed
characteristics of participants in these cohorts can be found in
Supplementary Material, Table S1. After applying exclusion cri-
teria, a total of 6510 women were included in the analysis. Ad-
mixture analyses showed that the percentage of African
ancestry in these women ranged from 75.5 to 83.5%. The
mean age at natural menopause ranged from 48.2 to 50.2 years
old across cohorts. The majority of the women were recruited
from the southern part of the USA.
Meta-analysis for age at natural menopause
We analyzed the association of 3.25 million genotyped and
imputed SNPs with age at natural menopause in two steps.
First in each cohort, we performed linear regression analyses,
using an additive genetic model, with each SNP coded as a
count of the number of minor alleles (0, 1 or 2 for genotyped
SNPs and raw dosage values for imputed SNPs) and age at meno-
pause as the response variable. To correct for global ancestry
effects, ancestry background of participants was estimated sep-
arately in each cohort using principal component analyses
(PCA). Recruitment sites and up to the first 10 principal compo-
nents (PCs) were used as covariates. We performed
meta-analysis across all 11 studies using association results
from each cohort. SNPs found in only one cohort or genotyped
in fewer than 1000 participants were excluded. Manhattan and
quantile–quantile plots from the meta-analysis can be found in
Supplementary Material, Figure S1. None of the associations
achieved genome-wide significance (P-value , 5 × 1028).
Results for the top 10 SNPs with the lowest P-values are
shown in Supplementary Material, Table S2. rs2165706,
located in the intergenic region on chromosome 17, had the
lowest P-value at 1.65 × 1026.
Replication of loci previously identified in women
of European ancestry
We hypothesized that loci that have been previously identified as
associated with age at menopause in women of European ances-
try would also be associated with age at menopause in
African-American women. We took a broad approach in select-
ing SNPs in these loci for replication in which we included all
SNPs reported to-date in European women without removing de-
pendent signals. As information on linkage disequilibrium (LD)
was not available for all SNPs, we did not want to miss true
signals by prefiltering the list of reported SNPs. Previously
reported SNPs in European women included 29 discovered in
GWAS and meta-analysis study with P-values ,1027 and 12
SNPs with P-values not reaching genome-wide significance
(,1024) (17–19). These SNPs clustered 30 loci: RHBDL2,
EXO1, FNDC4, TLK1, METAP1D, HELQ, RNF44, UIMC1/
HK3, SYCP2L, BAT2, ASH2L, FSHB/MPPED2, PRIM1,
KPNA3, TDRD3, POLG, GSPT1, BRSK1/TMEM150B,
NLRP11, MCM8, CLDN11, SLC44A4, GPR124, DYNC1H1,
BANP, chr2q23.3, chr7q22.3, chr9q21.31, chr11q25 and
chr13q34. We also included seven SNPs located in F5,
CYP1B1, ESR1, AMHR2, HSDB1, APOE that were implicated
in candidate gene studies in European women (27–33). We
also sought to identify additional signals in the LD block sur-
rounding these index SNPs.
Loci on chromosome 1 (RHBDL2), 5 (HK3/UMC1), 12
(PRIM1), 19 (BRSK1/TMEM150B), 20 (MCM8) and AMHR2
are associated with age at menopause in African-American
women
HK3/UMC1 locus on chromosome 5
Five correlated SNPs (rs2278493, rs691141, rs7718874,
rs365132 and rs402511) have been reported in association
with age at menopause at the HK3/UMC1 locus on chromosome
5 (17). Since these SNPs were identified in different cohorts of
European ancestry, we first assessed whether they represented
the same signal from this region by looking at the LD relation-
ships among these SNPs in Europeans. We used the HapMapII
CEU cohort as a proxy for Europeans and found these five
SNPs likely reflected the same signal, thus allowing us to
perform only one test at a significance level of 0.05. Of the five
SNPs, only rs402511 was significant (P ¼ 0.042) while
rs365132 and rs7718874 showed similar magnitude of
P-values (P ¼ 0.052 and 0.063) (Table 1). The effect sizes for
rs402511, rs365132 and rs77188754 were 0.205, 0.188 and
20.196, respectively, slightly attenuated compared with those
reported in European women (0.39, 0.287 and 20.39, respect-
ively, from initial discovery stage). To fine-map the signal in
this locus, we examined the LD structure in the HapMapII YRI
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1 (39152972) T 0.689 (0.013) 0.206 (0.095) 0.031# 6510 0.24 9.08 × 10217 RHBDL2 Intron – – H3K4Me1 Weak enhancer
rs1635501
j
1 (240107398) T 0.479 (0.019) 20.111 (0.083) 0.178 6478 0.16 8.46e10210 EXO1 Intron – – – –
rs2303369
j
2 (27568920) T 0.369 (0.012) 0.031 (0.086) 0.721 6510 20.17 2.25 × 10212 FNDC4 Intron – – – –
rs10183486
j
2 (171699217) T 0.578 (0.015) 20.028 (0.083) 0.732 6502 20.19 2.21 × 10214 TLK1 Intron – – – –
rs4693089
j
4 (84592646) A 0.235 (0.014) 0.122 (0.099) 0.223 6510 20.22 2.38 × 10219 HELQ Intron – – – –
rs2278493
k
5 (176247040) T 0.139 (0.009) 20.092 (0.118) 0.438 6489 20.3 7.20 × 1028 HK3 Intron – – – Repressed
rs691141
k
5 (176255904) A 0.424 (0.008) 20.026 (0.082) 0.753 6495 0.36 3.90 × 10212 HK3 Intron – 15 – Repressed
rs3762971
l




5 (176290671) A 0.210 (0.011) 20.196 (0.101) 0.052 6509 20.39 1.30 × 10213 UIMC1 Intron – – – –
rs365132i,j,k 5 (176311180) T 0.791 (0.011) 0.188 (0.101) 0.062 6508 0.39 /0.28 8.4 × 10214/
9.11 × 10232
UIMC1 Synony-mous – – – –
rs402511
k
5 (176367046) A 0.793 (0.010) 0.205 (0.101) 0.042# 6510 0.39 1.40 × 10213 UIMC1/
ZNF346




rs2153157j,k 6 (11005474) A 0.709 (0.010) 0.063 (0.091) 0.487 6492 0.29 /0.16 5.4 × 1028/
7.76 × 10212
SYCP2L Intron – – – –
rs1046089
j
6 (31710946) A 0.492 (0.014) 20.035 (0.083) 0.672 6469 20.21 1.63 × 10216 BAT2 Missense – – – –
rs2517388
j
8 (38096889) T 0.746 (0.027) 0.009 (0.123) 0.942 6509 20.26 9.31 × 10215 ASH2L Intron – 15 – –
rs12294104
j
11 (30339475) T 0.097 (0.008) 0.046 (0.137) 0.736 6508 0.22 1.46 × 10211 FSHB/MPPED2 Intergenic – – H3K27Ac Weak enhancer






















13 (60011740) A 0.279 (0.008) 0.108 (0.092) 0.239 6510 0.17 9.53 × 10211 TDRD3 Intron – – – –
rs7333181
k
13 (111019298) A 0.105 (0.007) 0.128 (0.137) 0.351 6510 0.52 2.50 × 1028 TEX29/SOX1 Intergenic – – – –
rs2307449
j
15 (87664932) T 0.379 (0.012) 0.112 (0.084) 0.181 6487 0.18 3.56 × 10213 POLG Intron – – – –
rs10852344
j
16 (11924420) T 0.177 (0.014) 20.190 (0.110) 0.085 6508 20.16 1.01 × 10211 GSPT1/
TNFRSF17
Intergenic – – – Repressed
rs12611091
k
19 (60492141) T 0.524 (0.015) 20.136 (0.092) 0.141 6503 20.33 6.60 × 10210 BRSK1 Intron – – – –
rs1551562
k
19 (60506693) A 0.875 (0.012) 0.374 (0.163) 0.021# 6510 0.43 /0.42 2.6 × 10212/
1.04 × 1029
BRSK1 Intron – – – Weak enhancer
rs1172822
k




BRSK1 Intron POV2F2 (126) 19 – Weak enhancer
rs7246479
k
19 (60516144) T 0.122 (0.037) 0.141 (0.261) 0.59 2990 0.36 2.30 × 10212 TMEM150B Missense – – – Weak enhancer
rs2384687
k
19 (60523000) A 0.599 (0.015) 0.258 (0.084) 2.13 × 1023# 6510 0.47/0.38 2.40 × 10218/
1.39 × 10210
TMEM150B Intron SIX5 (1000),
TAF1 (68)








19 (60525566) A 0.537 (0.019) 0.207 (0.089) 0.020# 6510 0.40/0.30 1.10 × 10214/
3.91 × 1028













20 (5883385) T 0.086 (0.007) 0.139 (0.145) 0.339 6501 20.49 9.71 × 10211 MCM8 Intron – – – –
rs16991615j,k 20 (5896227) A 0.013 (0.003) 0.346 (0.452) 0.444 4390 1.07/0.94 1.2 × 10221/
1.42 × 10273


































cohort as a proxy for African Americans. rs402511, rs365132
and rs77188754 were in perfect LD in Africans while the
other two SNPs were not, indicating the functional SNP must
be in LD with rs402511 in both European and African ethnic
backgrounds. Due to the extent of LD in this region, we were
only able to narrow the location of the signal down to
167.8 kb (chr5: 176 257 335–176 425 163, hg18) from
169.2 kb (chr5: 176 255 904–176 425 163, hg18) (Fig. 1A,
CEU cohort on the left panel, YRI cohort on the right panel)
(Table 2).
To investigate whether there was any additional signal at this
locus, we identified all SNPs in this LD block and determined
that the number of effective tests is 29. We found that
rs3762971 was also associated with age at menopause (P ¼
1.25 × 1023, b ¼ 20.551). rs3762971 is in low LD with
rs402511 in both European (r2 ¼ 0.25) and African cohorts
(r2 ¼ 0.28) (Fig. 1B, CEU cohort on the left panel, YRI cohort
on the right panel). We performed conditional analyses incorp-
orating both SNPs in the model to test the hypothesis that they
may be two independent signals. We found that rs3762971
may not be an independent signal from rs402511 (P ¼ 0.07 for
rs3762971 at a-level of 0.05).
BRSK1/TMEM150B locus on chromosome 19
Seven moderately correlated SNPs at the BRSK1/TMEM150B
locus on chromosome 19 (rs1172822, rs2384687, rs897798,
rs7246479, rs1551562, rs12611091 and rs11668344) were pre-
viously reported to be associated with age at menopause. All
but two SNPs (rs7246479, rs12611091) replicated in our
cohorts of African-American women (P , 0.05). These two
SNPs are not at high LD with the other five SNPs at this locus
in Africans (Fig. 2). Rs11668344 had the lowest P-value of
6.54 × 1024. Its effect size was 0.311 in our cohorts, slightly
smaller than the effect size reported in European Americans
(0.41 from the combined analysis (19)).
MCM8 locus on chromosome 20
Two SNPs identified to be associated with age at menopause,
rs16991615 and rs236114, were located at the MCM8 locus on
chromosome 20. Neither replicated in our cohort (rs16991615,
P ¼ 0.44; rs236114, P ¼ 0.34) (Table 1). The minor allele fre-
quencies of these two SNPs differed dramatically between Eur-
opeans and Africans, with much lower frequencies found in
Africans (rs16991615: 7% versus 1.3%; rs236114: 21% versus
8.6%, respectively) (18,19). We sought to test all SNPs in high
LD with these two SNPs in African Americans at this locus to
confirm that the signal was not in high LD with these two
SNPs; however, no LD information exists for rs16991615 in
HapMapII YRI (Fig. 3A). SNPs in high LD with rs236114 at
this locus all had similar P-values (Fig. 3B). We next investi-
gated if there was any signal from this locus associated with
age at menopause by testing all SNPs on the LD block surround-
ing this locus. Rs6139882 was found to be significant (P ¼
1.35 × 1023 at a-level of 2.78 × 1023). Its minor allele fre-
quency (MAF) is 5.3% and the effect size is 20.8495. In Eur-
opeans, the LD between rs6139882 and the two reported SNPs
are very low (r2 ¼ 0.010 with rs16991615; r2 ¼ 0.027 with
rs236114). Rs6139882 is not in LD with rs236114 (r2 ¼
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Americans, indicating that rs6139882 is likely a secondary
signal from this locus.
RHBDL2 locus on chromosome 1, PRIM1 locus on chromosome
12 and AMHR2 locus
Of the 16 SNPs identified only by a meta-analysis of European
cohorts, we replicated two loci (rs4246511 at RHBDL2 on
chromosome 1, P ¼ 0.031; rs2277339 at PRIM1 on chromo-
some 12, P ¼ 0.022) in African-American cohorts (Table 1).
The effect sizes for rs4246511 and rs2277339 were 0.21 and
0.36 in our cohorts, similar to those reported previously (0.24
and 0.38, respectively, from the combined analysis (19)). In add-
ition, 11 loci showed direction of effects consistent with previous
reports.
Several candidate gene studies in women with European an-
cestry identified seven SNPs located in six loci (F5, CYP1B1,
ESR1, AMHR2, HSDB1, APOE) as associated with age at meno-
pause (27–33). We investigated whether these SNPs are also
associated with this trait in African-American women. Of the
seven SNPs, only rs2002555 located in AMHR2 was shown to
be associated with our phenotype (P ¼ 0.0062).
DISCUSSION
Genetic factors play an important role in determining the timing
of natural menopause. These factors have been investigated most
extensively in women of European ancestry but relatively little
genetic research has been done in African-American women.
Our study in African-American women is the largest and most
comprehensive conducted to-date. In this study, we report that
the mean age of women who underwent natural menopause
ranged from 48.2 to 50.2 years of age across cohorts, which is
earlier than women of European ancestry (1–3). Prior epidemio-
logical studies have also shown that African-American women
tend to experience menopause sooner (34,37). Differences in
the timing of this universal event suggest that different modifiers
might exist in different ethnic backgrounds.
Previous GWAS in women of European ancestry identified 21
loci associated with age at menopause (17–19). We investigated
the relevance of these loci in 6510 African-American women
and replicated rs4246511 in RHBDL2 on chromosome 1,
rs2277339 in PRIM1 on chromosome 12, HK3/UMC1 locus on
chromosome 5, BRSK1/TMEM150B locus on chromosome 19
and MCM8 on chromosome 20. Rs4246511 is located in the
Figure 1. Association between age at menopause and chromosome 5 locus surrounding rs402511. Each panel shows the pairwise disequilibrium between SNPs in this
region with rs402511 (A, colored in purple) and rs3762791 (B, colored in purple) estimated from HapMap CEU data (left panels) and HapMap YRI data (right panels).
The r2 values are color coded according to the scale on each panel. The y-axis shows the P-values for strength of associations for each SNP in the region. The LD block
where the signals reside is highlighted. rs402511 is associated with age at menopause in GWAS of women with European ancestry while a potential secondary signal,
rs3762971, is found in women with African ancestry (17). r2 between rs3762971 and rs402511 is low in both HapMap CEU and YRI. The strongest signal in this
genomic region reported from meta-analyses of European cohorts (rs365132) is in tight LD with rs402511 in both HapMap CEU (r2 ¼ 0.93) and YRI (r2 ¼ 1) popula-
tions, suggesting rs402511 and rs365132 represent the same signal.
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intron of RHBDL2 (rhomboid, veinlet-like 2), a protein thought
to release soluble growth factors by proteolytic cleavage of
certain membrane-bound substrates (38). Experimental data
from the ENCODE project suggested that this region may
have weak enhancer activity (39). Rs2277339 is a missense
SNP located in PRIM1, a protein involved in DNA replication
(40). Results from the ENCODE project showed that it is an
active regulatory site where many transcription factors, such as
TAF1, HEY1, PAX5-20 and histone markers, such as
H3K4Me3 and H3K27Ac, bind. Since both RHBLD2 and
PRIM1 are involved in DNA repair, we hypothesize that there
may be some interaction between the DNA repair pathway and
the pathway leading to menopause. We uncovered two signals
at HK3/UIMC1 locus on chromosome 5: rs402511 and
rs3762971. Both of them are located in the intergenic region,
one upstream of HK3 and one downstream of UIMC1. The
histone-binding patterns indicate that they may have weak en-
hancer activities and rs3762971 may be a part of an insulator se-
quence. All of the SNPs we replicated at BRSK1/TMEM150B
locus are located in the introns and have been predicted to
have weak enhancer and repressor activities. Rs16991615, a
missense SNP at the MCM8 locus on chromosome 20, has the
lowest P-value in studies of Caucasian women; however, it did
not replicate in our cohort. One reason could be due to the differ-
ent MAF in two ethnic groups (7% in Caucasians and 1.3% in
Africans), requiring a far larger African-American sample to
detect its effect. The effect size for rs16991615 in African Amer-
icans in our studies was 0.346 (s.e. ¼ 0.452) while it was reported
to be 1.07 (from combined analysis) in Caucasians (19). We,
however, did uncover another signal at MCM8 (rs6139882
located in the intronic region of MCM8). It is plausible that
there are multiple signals at this locus, resulting in a similar
effect on MCM8 regulation. A recent study in African Americans
also could not replicate the association between rs16991615 and
age at menopause while another study in Hispanics showed the as-
sociation, supporting a likely hypothesis that the causal variant at
the MCM8 locus is in LD with rs16991615 in Caucasians and with
rs6139882 in African Americans (41,42). MCM8 is expressed
within the oocytes in the follicles of the human ovary and that at
least in Caucasian women, rs16991615 is associated with antral
follicle count, which reflects ovarian reserve (43). These findings
all support the hypothesis that MCM8 is involved in the pathway
leading to menopause.
Several small candidate gene studies suggested F5, CYP1B1,
ESR1, AMHR2, HSDB1 and APOE may affect the timing of
menopause. A recent study in a large number of women with
Table 2. Replication of loci identified from candidate gene studies in European cohorts
Gene SNP Chromosome
(position)a




F5 rs6020 1 (167785736) T/C 0.275 (0.018) 20.067 (0.094) 0.473 6195 2 0.03 (31)
CYP1B1 rs1056836 2 (38151707) C/G 0.755 (0.016) 20.025 (0.097) 0.794 6293 +/+ 0.004 (29)/0.82(33)
CYP1B1 rs1800440 2 (38151643) T/C 0.954 (0.006) 20.069 (0.21) 0.744 5918 +/+ 0.018 (27)/0.25 (33)
ESR1 rs2234693 6 (152205028) T/C 0.462 (0.014) 0.159 (0.081) 0.050 6502 2/2 0.0 3 (32)/0.12 (33)
AMHR2 rs2002555 12 (52103504) A/G 0.871 (0.008) 0.332 (0.122) 0.006∗ 6508 +/+ 0.054 (28)/0.68 (33)
HSDB1 rs2830 17 (37958089) A/G 0.686 (0.015) 20.131 (0.091) 0.151 6510 2/2 0.03 (30)/0.20 (33)
APOE rs7412 19 (50103919) T/C 0.098 (0.003) 20.334 (0.425) 0.431 720 2 0.03 (31)
∗P-value is significant at a ¼ 0.05.
Freq, frequency; s.e., standard error.
aPositions are in NCBI36 coordinates.
bMinor/major alleles. Average frequencies and effect sizes of minor alleles across all cohorts are listed.
Figure 2. Association between age at menopause and chromosome 19 locus.
Each panel shows the pairwise disequilibrium between SNPs in this region
with rs11668344 (colored in purple) estimated from HapMap CEU data (A)
and HapMap YRI data (B). The r2 values are color coded according to the
scale on each panel. The y-axis shows the P-values for strength of associations
for each SNP in the region. The LD block where the signals reside is highlighted.
Five of the eight previously reported signals (rs1551562, rs1172822, rs2384687,
rs11668344 and rs897798) in this region replicated in the current study. They
likely all represent the same signal as they are in high LD with one another in
both HapMap CEU and YRI populations. rs11668344 has the lowest P-value
at this locus in our cohorts.
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European ancestry did not replicate any of these genes (33). Of
these genes, we only found rs2002555 at AMHR2 to be signifi-
cantly associated with age at menopause. AMHR2 is a gene
coded for AMH (anti-Mullerian hormone) receptor, type II. A
missense SNP in this locus is associated with sex determination
in the tiger pufferfish, suggesting that AMHR2 played a role in
the reproductive pathway across species (44). In humans,
AMH binds to AMHR2. AMH is expressed by granulosa cells
of the ovary during the reproductive years, setting the pace at
which follicles reenter meiosis and growth (45). Hence, AMH
level is associated with the rate of depletion of the primordial fol-
licle pool and has been shown to be a good predictor for age at
menopause (46).
Results from our meta-analysis of African-American women
confirm some, but not all, of the findings in women of European
ancestry. One reason is our modest sample size. With our sample
Figure 3. Association between age at menopause and chromosome 20 locus surrounding rs16991615. Each panel shows the pairwise disequilibrium between SNPs in
this region with rs16991615 (A, colored in purple), rs236114 (B, colored in purple), and a likely secondary signal, rs6139882 (C, colored in purple) estimated from
HapMap CEU data (left panels) and HapMap YRI data (right panels). The r2 values are color coded according to the scale on each panel. The y-axis shows the P-values
for strength of associations for each SNP in the region. The LD block where the signals reside is highlighted. rs16991615 has a low MAF in HapMap YRI population
and thus, there is no available LD information with other SNPs at this locus.
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size, however, we have at least 80% power to replicate SNPs with
magnitude of effect as low as 0.2 in Caucasian women (Fig. 4;
Supplementary Material, Table S4). These SNPs were located
in five of the 21 loci identified from previous GWAS. Another
three loci could be replicated with at least 60% power.
Another reason is that even though menopause is a universal
event determined mostly by genetic factors, there exist many
modifiers in the associated loci. The complex genomic structures
in African Americans make it more difficult to distinguish modi-
fiers with smaller effects from background mutation due to the
existence of more variants. Due to the different LD patterns in
African Americans, the identified GWAS hits could be proxys
for the causal variant, which may not be well genotyped or
imputed in our data. Our meta-analysis supports the notion that
genetic variants influencing menopause timing identified in
European populations are also important in women of African
ancestry residing in the USA. More functional experiments are




Women’s Health Initiative (WHI) is a long-term national health
study that focuses on strategies for preventing common diseases
such as heart disease, cancer and fracture in postmenopausal
women. A total of 161,838 women aged 50–79 years old were
recruited from 40 clinical centers in the USA between 1993
and 1998. WHI consists of an observational study, two clinical
trials of postmenopausal hormone therapy (estrogen alone or es-
trogen plus progestin), a calcium and vitamin D supplement trial,
and a dietary modification trial (47). Study recruitment and ex-
clusion criteria have been described previously (48). Study pro-
tocols and consent forms were approved by the institutional
review boards at all participating institutions. Medical history
was updated annually (for women in the observational study)
or semiannually (for women in the clinical trials) by mail and/
or telephone questionnaires. The WHI SNP Health Association
Resource (WHI-SHARe) includes 8515 self-identified African-
American women from WHI who provided consent for DNA
analysis. Approximately 1% of samples could not be genotyped.
Samples in the following categories were excluded: with call
rates ,95%, in duplicates, or with genotype calls on the Y
chromosome. The relatedness among participants was investi-
gated and there were 97 sets of monozygotic twins, parent–off-
spring, full-siblings and half-siblings. After retaining only one
individual from each set, our final sample size was 8421
African-American women. Genotyping and quality control: all
WHI samples, plus 2% blinded duplicates, were genotyped at
Affymetrix Inc. (www.affymetrix.com) on the Genome-wide
Human SNP Array 6.0 (909 622 SNPs). SNPs that were
located on the Y chromosome or were Affymetrix quality
control probes (not intended for analysis) were excluded (n ¼
3280). We also excluded SNPs that had call rates ,95% and con-
cordance rates ,98%, leaving us 871 309 SNPs available for use
in this study. The average concordance for blinded duplicate
samples was 99.8%, and the average sample call rate after
SNP exclusions was 99.8%. Imputation: imputation for WHI
samples was performed in MACH 1.0.16 (http://www.sph.um
ich.edu/csg/abecasis/mach/) using a reference panel composed
of 60 unrelated CEU and 60 unrelated YRI samples from
HapMap release 22 (49). Phenotype definition: the questions
related to menopausal status on WHI enrollment questionnaires
were: ‘How old were you when you last had any menstrual bleed-
ing? (If you are still having menstrual bleeding or periods, enter
your current age.)’, ‘When was the last time you had any men-
strual bleeding or spotting?’, ‘Did you ever have a hysterec-
tomy?’ and ‘Did you ever have an operation to have one or
both of your ovaries taken out?’ Eligible WHI participants
were defined as those who had at least one ovary intact before
the cease of menses and who reported having last menstrual
bleeding or spotting over 12 months ago at the time of the
study. WHI Participants with endometrial and cervical cancer
history were removed. Population Stratification Correction:
EIGENSTRAT was used to perform separate PCA to compute
the first 10 PC for each individual (50). The reference panel
was composed of 475 ancestors from HapMap populations and
the Human Genome Diversity Panel. One hundred and nine
CEU and 108 YRI individuals were taken from the HapMap.
PCA analyses were performed on these two groups separately
using EIGENSTRAT. Each population was subjected to five
rounds of outlier removal based on the resulting PC information.
In total, two outliers were identified in each group, bringing the
final population sizes to 107 CEU and 106 YRI. Sixty-three indi-
viduals in HGDP sampled from the Americans (8 Surui, 22
Mayans, 13 Karitiana, 14 Pima, 6 Colombian) and 225 East
Asians were subjected to the same EIGENSTRAT PCA-based
outlier removal procedure as for the HapMap individuals,
leaving 200 East Asian individuals and 62 Native Americans.
178 101 SNPs overlapping the HGDP, HapMap and WHI sub-
jects were used in EIGENSTRAT. To complement the PCA ana-
lysis, frappe was used to estimate the relative contributions of all
four ancestral groups to every admixed individual (51). A total of
656 852 autosomal SNPs were used in the frappe analysis.
The GENOA is a community-based study of hypertensive sib-
ships that aims to identify genes influencing blood pressure
Figure 4. Comparisons of effect magnitude of loci associated with age at meno-
pause between women with European and African ancestry. Each point repre-
sents a previously identified locus associated with age at menopause in women
with European ancestry. Loci replicated in the current African-American
cohorts are colored in black. The dash line indicates the theoretical x ¼ y line.
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(52,53). In the initial phase of the GENOA study (9/1995 to 6/
2001), sibships containing ≥2 individuals with essential hyper-
tension diagnosed before age 60 years were selected for partici-
pation. At the Jackson, MS field center, 1854 African Americans
were enrolled. Participants returned in a second phase of
GENOA (December 2000 to June 2004) for physical examin-
ation and measurement of non-conventional and novel risk
factors. Genotyping and Quality Control: all samples were gen-
otyped on Affymetrix Genome-wide human SNP array 6.0. Im-
putation: a single step approach was performed in MACH 1.0.16
(http://www.sph.umich.edu/csg/abecasis/mach/) using a refer-
ence panel composed of 60 unrelated CEU and 60 unrelated
YRI samples from HapMap release 22 (49). Phenotype defin-
ition: subjects were asked whether or not they had reached meno-
pause, defined as the cessation of natural menses for at least 12
months. Subjects that reported reaching menopause were
asked ‘In what year or how old were you when you reached
menopause?’. Subjects with menopause induced by surgery, ra-
diation or chemotherapy were excluded. Population Stratifica-
tion Correction: PCs for individuals were calculated based on
all SNPs in the dataset without a reference panel using SNP
and Variation Suite 7 (SVS7) from Golden Helix (http://www.
goldenhelix.com/SNP_Variation/). The relative contribution
of CEU and YRI in GENOA individuals were assessed on a
panel of 385 ancestry informative markers using the STRUC-
TURE program (54).
The Health ABC is a NIA-sponsored ongoing cohort study of
the factors that contribute to incident disability and the decline in
function of healthier older persons, with a particular emphasis on
changes in body composition in old age. Health ABC enrolled
well functioning, community-dwelling black (n ¼ 1281) and
white (n ¼ 1794) men and women aged 70–79 years between
April 1997 and June 1998. Participants were recruited from a
random sample of white and all black Medicare eligible residents
in the Pittsburgh, PA and Memphis, TN, metropolitan areas. The
key components of Health ABC include a baseline exam, annual
follow-up clinical exams and phone contacts every 6 months to
identify major health events and document functional status
between clinic visits. Genotyping and Quality Control: genotyp-
ing was done in 1663 Caucasians and 1139 African Americans
using the Illumina Human 1M-Duo BeadChip System at the
Center for Inherited Disease Research (CIDR). SNPs were
excluded if their call rate was ,97%, Hardy–Weinberg equilib-
rium P-value was ,1026, or major allele frequency was ,1%.
Imputation: MACH 1.0.16 was used for imputation, using
HapMap CEU release 22, build 36, as the reference panel.
Phenotype Definition: participants who reported hysterectomy
or ovariectomy (bilateral or otherwise) were excluded. Popula-
tion Stratification Correction: EIGENSTRAT was used to calcu-
late PCs for individuals using all SNPs that passed quality
control.
The HANDLS is an interdisciplinary, community-based, pro-
spective longitudinal epidemiologic study examining the influ-
ences of race and socioeconomic status (SES) on the
development of age-related health disparities among socio-
economically diverse African Americans and whites in Balti-
more. This study investigates whether health disparities
develop or persist due to differences in SES, differences in
race or their interaction. The HANDLS design is an area prob-
ability sample of Baltimore based on the 2000 Census. The
study protocol facilitated our ability to recruit 3722 participants
from Baltimore, MD with mean age 47.7 (range 30–64) years
and 2200 African Americans (59%) and 1522 whites (41%).
One thousand and twenty-four participants, a subset of partici-
pants self-reporting as African Americans, were genotyped at
the Laboratory of Neurogenetics located in the National Institute
on Aging in National Institutes of Health. Genotyping and
Quality Control: samples were genotyped at 907 763 SNPs at
the equivalent of Illumina 1M SNP coverage (709 samples
using Illumina 1M and 1Mduo arrays, the remainder using a
combination of 550K, 370K, 510S and 240S to equate the
million SNP level of coverage), passing inclusion criteria into
the genetic component of the study. Initial inclusion criteria
for genetic data include concordance between self-reported
sex and sex estimated from X chromosome heterogeneity,
.95% call rate per participant (across all equivalent arrays),
concordance between self-reported African ancestry and ances-
try confirmed by analyses of genotyped SNPs, and no cryptic re-
latedness to any other samples at a level of proportional sharing
of genotypes .15% (effectively excluding first cousins and
closer relatives from the set of probands used in analyses). In
addition, SNPs were filtered for HWE P-value of .1027,
missing by haplotype P-values of .1027, MAF . 0.01 and
call rate of .95%. Basic genotype quality control and data man-
agement were conducted using PLINKv1.06 (55). Cryptic re-
latedness was estimated via pairwise identity by descent
analyses in PLINK and confirmed using RELPAIR (56). Imput-
ation: imputation was performed in MACH 1.0.16 (http://www.
sph.umich.edu/csg/abecasis/mach/) using a reference panel
composed of 60 unrelated CEU and 60 unrelated YRI samples
from HapMap release 22 (49). A two-stage process was used:
first estimating recombination and crossover events in a
random sample of 200 participants, then based on this data and
the reference haplotypes, 200 iterations of the maximum likeli-
hood model were used to estimate genotype dosages for imputed
SNPs. Phenotype Definition: age at natural menopause was
defined as the age at the last menstrual period which occurred
naturally. Only women with natural menopause between the
ages of 40 and 60 years were included. Subjects were asked
‘what was your age at menopause in years?’ Population Stratifi-
cation Correction: ancestry estimates were assessed using both
STRUCTUREv2.3 (54,57,58) and the multidimensional
scaling (MDS) function in PLINKv1.06 (55). In the MDS ana-
lysis, HANDLS participants were clustered with data made
available from HapMap Phase 3 for the YRI, ASW, CEU, TSI,
JPT and CHB populations, using a set of 36 892 linkage-
disequilibrium-pruned SNPs common to each population. This
set of SNPs were chosen as they are not in r2. 0.20 with
another SNP in overlapping sliding windows of 100 SNPs in
the ASW samples. HANDLS participants with component
vector estimates consistent with the HapMap ASW samples
for the first 4 component vectors were included. In addition,
the 1024 quality controlled HANDLS samples were later clus-
tered among themselves using MDS to generate 10 component
vectors estimating internal population structure within the
HANDLS study.
MESA family study is a multicenter, family based study whose
goal is to locate and identify genes contributing to the genetic
risk for cardiovascular disease, by looking at the early changes
of atherosclerosis within families (mainly siblings). The
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MESA family cohort was recruited from the six MESA Field
Centers. MESA family participants underwent the same examin-
ation as MESA participants during May 2004–May 2007. In a
small proportion of subjects, parents of MESA index subjects
participating in MESA family were studied but only to have
blood drawn for genotyping. DNA was extracted and lympho-
cytes immortalized for 1633 non-classic MESA family
members (950 African Americans and 683 Hispanic Americans)
from 594 families, yielding 3026 sibpairs. Genotyping and
Quality Control: samples were genotyped on the Affymetrix
Genome-wide human SNP array 6.0. Genotype calls were per-
formed using Birdseed v1.33. We used PLINK, EIGENSTRAT
and PREST-Plus software for quality control (59). Imputation:
IMPUTE version 2.1.0 was used to perform imputation with
HapMap Phases I and II (CEU, YRI, CHB, JPT populations)
as the reference panel (release 22—NCBI Build 36 (dbSNP
b126)) (60,61). Phenotype Definition: age at natural menopause
was defined as the age at the last menstrual period which oc-
curred naturally. Only women with natural menopause
between the ages of 40 and 60 years were included. Subjects
were asked ‘what was your age at menopause in years’. Popula-
tion Stratification Correction: EIGENSTRAT was used to calcu-
late two population stratification PCAs which were used as
regression covariates (50).
CARe Consortium consisted of nine cohorts, of which four
were included in the current study (62). These cohorts were: Ath-
erosclerosis Risk in Communities (ARIC), Cardiovascular
Health Study (CHS), Jackson Heart Study (JHS) and MESA.
The CHS is a population-based study of risk factors for cardio-
vascular disease in older adults, sponsored by the National Heart,
Lung and Blood Institute. Men and women aged 65 and older
were recruited from random samples of Health Care Financing
Administration eligibility lists in four US communities in
1989–90 (63,64). In 1992–93, the original sample was supple-
mented with additional recruitment of African Americans at
three of the study sites. Genotyping and Quality Control: geno-
typing was performed at the General Clinical Research
Center’s Phenotyping/Genotyping Laboratory at Cedars-Sinai
Medical Center using the Illumina HumanOmni1-Quad_v1
BeadChip system. Genotypes were called using the Illumina
GenomeStudio software. The following exclusions were
applied to identify a final set of 963 248 SNPs (940 567 auto-
somal and 22 681 X): call rate ,97%, HWE P , 1025, .1 du-
plicate error or Mendelian inconsistency (for reference CEPH
trios), heterozygote frequency ¼ 0. Imputation: imputation for
CHS samples was performed using BEAGLE version 3.2.1
using the default value of 10 iterations (65). Imputation was per-
formed in a two-step process. The data were imputed to HapMap
Phase III using reference panels from the ASW, YRI and CEU
panels. They were separately imputed using HapMap Phase II
using the CEU and YRI reference panels (build 36). For each im-
putation, the observed data were subset to the markers also
observed in the given HapMap reference panel. The resulting
two sets of imputed data were merged. If a marker was
imputed in both the Phase II and Phase III data the Phase III
data were used. Directly genotyped SNPs that were in the
HapMap samples were not overwritten, but any missing data
for a genotyped SNP were filled in using imputation. The
final number SNPs in the imputed data set were 2 770 583.
Phenotype Definition: age at natural menopause was assessed
retrospectively by questionnaire and included age at last men-
strual period, and age at hysterectomy or ovary removal, if
either. Use of hormone replacement therapy was ascertained at
clinic visits from medicine bottles, as previously described
(66). Women with menopause due to hysterectomy and/or bilat-
eral oophorectomy and women using hormone replacement
therapy before menopause were excluded. Population Stratifica-
tion Correction: PCs were computed based on 97 404 genotyped
SNPs from the Illumina Omni 1M chip (approximately every
10th SNP on the array) using EIGENSTRAT (50).
The ARIC is a multicenter prospective investigation of athero-
sclerotic disease in a predominantly biracial population (67).
Men and women aged 45–64 years at baseline were recruited
from four communities: Forsyth County, North Carolina;
Jackson, Mississippi; suburban areas of Minneapolis, Minnesota
and Washington County, Maryland. A total of 15 792 indivi-
duals participated in the baseline examination in 1987–89
when blood was drawn for DNA extraction and participants con-
sented to genetic testing. Genotype data were available on 2989
self-reported African-American individuals. Genotyping and
Quality Control: samples were genotyped at the Broad Institute
using the Affymetirx Genome-Wide Human SNP Array 6.0.
Two methods of DNA quality control metrics were assessed
on the samples (59). Genotypes were called using Birdseed
v1.33. Quality control steps were performed using the software
PLINK, EIGENSTRAT and PREST-Plus (59). Imputation: im-
putation was performed in MACH 1.0.16 (http://www.sph.um
ich.edu/csg/abecasis/mach/) using a reference panel composed
of 60 unrelated CEU and 60 unrelated YRI samples from
HapMap release 22 (49). Imputation based on Affymetrix data
resulted in an allelic concordance rate of 95.6%, calculated
as 1 – 1/2∗|imputed_dosage 2 chip_dosage|. This rate is com-
parable with rates calculated for individuals of African descent
imputed with the HapMap 2 YRI individuals. For each
imputed sample, imputation was performed in two steps. For
the first step, individuals with pedigree relatedness or cryptic re-
latedness (pi_hat . 0.05) were filtered. A subset of individuals
was randomly extracted from each panel and used to generate re-
combination and error rate estimates for the corresponding
sample. In the second step, these rates were used to impute all
sample individuals across the entire reference panel. Imputation
results were filtered at an RSQ_HAT threshold of 0.3 and an
MAF threshold of 0.01. Phenotype Definition: a reproductive
history questionnaire was completed by all women in the
ARIC study at each study visit. The questionnaire included ques-
tions on whether they were currently menstruating, their age at
last menstrual period (in years) for those who were no longer
menstruating, as well as questions on whether and when they
had undergone surgery to remove their womb and/or ovaries,
or had undergone chemotherapy or radiation treatment. Age at
menopause was determined from each woman’s first report of
their age at menopause (age at last period), and restricted to
those that denied hysterectomy, denied removal of both
ovaries prior to cessation of menses, and denied any chemother-
apy or radiation treatment which stopped their menses. Only
such cases between the ages of 40 and 60 years were included.
Population Stratification Correction: EIGENSTRAT was used
to compute the first 10 PCs for each individual (50). The refer-
ence populations were composed of 1178 European Americans
and 756 Nigerians from the Yoruba region (59).
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The JHS is a community-based observational study whose
primary objective is to investigate causes of cardiovascular
disease in an African-American population. The cohort (N ¼
5301) was sampled from non-institutionalized African Amer-
icans 35–84 years old in urban and rural areas of three counties
in Mississippi (Hinds, Madison and Rankin) and involved four
components: (i) African Americans from Jackson, MS who
were also participants in the ARIC cohort (31%); (ii) a family
cohort of relatives of index participants (22%; all ages ≥ 21
included); (iii) individuals from randomly sampled households
from a commercial listing (17%) and (iv) a constrained volunteer
sample designed to reflect the demographics of the overall popu-
lation (30%) (68). This study was approved by the institutional
review board, and all subjects provided written informed
consent. Genotyping and Quality Control: samples were geno-
typed at the Broad Institute using the Affymetirx Genome-Wide
Human SNP Array 6.0. Two methods of DNA quality control
metrics were assessed on the samples (59). Genotypes were
called using Birdseed v1.33. Quality control steps were per-
formed using the software PLINK, EIGENSTRAT and
PREST-Plus (59). Imputation: imputation was performed in
MACH 1.0.16 (http://www.sph.umich.edu/csg/abecasis/mach/
) using a reference panel composed of 60 unrelated CEU and
60 unrelated YRI samples from HapMap release 22 (49). Imput-
ation based on Affymetrix data resulted in an allelic concordance
rate of 95.6%, calculated as 1 – 1/2∗|imputed_dosage –
chip_dosage|. This rate is comparable with rates calculated for
individuals of African descent imputed with the HapMap 2
YRI individuals. For each imputed sample, imputation was per-
formed in two steps. For the first step, individuals with pedigree
relatedness or cryptic relatedness (pi_hat . 0.05) were filtered.
A subset of individuals was randomly extracted from each panel
and used to generate recombination and error rate estimates for
the corresponding sample. In the second step, these rates were
used to impute all sample individuals across the entire reference
panel. Imputation results were filtered at an RSQ_HAT threshold
of 0.3 and an MAF threshold of 0.01. Phenotype Definition: only
women with data for genotype and age at natural menopause who
did not overlap with the ARIC cohort were included in the JHS
analysis (N ¼ 185). Age at natural menopause was defined as
the age at the last menstrual period which occurred naturally.
Only women with natural menopause between the ages of 40
and 60 years were included. Subjects were asked ‘what was
your age at menopause in years’. Population Stratification Cor-
rection: EIGENSTRAT was used to compute the first 10 PC
for each individual (50). The reference populations were com-
posed of 1178 European Americans and 756 Nigerians from
the Yoruba region (59).
The MESA is an NHLBI-funded study of the characteristics of
subclinical cardiovascular disease and the risk factors that
predict progression to clinically overt cardiovascular disease
(69). MESA researchers study a diverse, population-based
sample of 6814 asymptomatic men and women aged 45–84
recruited from six field centers across the United States: wake
Forest University, Columbia University, Johns Hopkins Univer-
sity, University of Minnesota, Northwestern University and Uni-
versity of California-Los Angeles. Five of the six sites recruited
African-American subjects. The first examination of MESA par-
ticipants took place over 2 years, from July 2000–July 2002.
Genotype data were available on 1646 African-American
individuals. Genotyping and Quality control: samples were gen-
otyped at the Broad Institute using the Affymetirx Genome-
Wide Human SNP Array 6.0. Two methods of DNA quality
control metrics were assessed on the samples (59). Genotypes
were called using Birdseed v1.33. Quality control steps were
performed using the software PLINK, EIGENSTRAT and
PREST-Plus (59). Imputation: imputation was performed in
MACH 1.0.16 (http://www.sph.umich.edu/csg/abecasis/mach/
) using a reference panel composed of 60 unrelated CEU and
60 unrelated YRI samples from HapMap release 22 (49). Imput-
ation based on Affymetrix data resulted in an allelic concordance
rate of 95.6%, calculated as 1 – 1/2∗|imputed_dosage –
chip_dosage|. This rate is comparable with rates calculated for
individuals of African descent imputed with the HapMap 2
YRI individuals. For each imputed sample, imputation was per-
formed in two steps. For the first step, individuals with pedigree
relatedness or cryptic relatedness (pi_hat . 0.05) were filtered.
A subset of individuals was randomly extracted from each panel
and used to generate recombination and error rate estimates for
the corresponding sample. In the second step, these rates were
used to impute all sample individuals across the entire reference
panel. Imputation results were filtered at an RSQ_HAT threshold
of 0.3 and an MAF threshold of 0.01. Phenotype Definition: age
at natural menopause was defined as the age at the last menstrual
period which occurred naturally. Only women with natural
menopause between the ages of 40 and 60 years were included.
Subjects were asked ‘what was your age at menopause in years’.
Population Stratification Correction: EIGENSTRAT was used
to compute the first 10 PCs for each individual (50). The refer-
ence populations were composed of 1178 European Americans
and 756 Nigerians from the Yoruba region (59).
Two cohorts from the AABC were included in the current
study: the Carolina Breast Cancer Study (CBCS) and The Multi-
ethnic Cohort Study (MEC). The other cohorts were excluded
due to the small size of subjects with available data (,100).
The control and case samples were treated as distinct cohorts.
The CBCS is a population-based case–control study con-
ducted between 1993 and 2001 in 24 counties of central and
eastern North Carolina (70). Cases were identified by rapid
case ascertainment system in cooperation with the North Caro-
lina Central Cancer Registry and controls were selected from
the North Carolina Division of Motor Vehicle and United
States Health Care Financing Administration beneficiary lists.
Participants’ ages ranged from 20 to 74 years. DNA samples
were provided from 656 African American cases with invasive
breast cancer and 608 African-American controls. Genotyping
and Quality control: genotyping in Stage 1 was conducted
using the Illumina Human1M-Duo BeadChip. We removed
samples with DNA concentrations ,20 ng/ml. Following geno-
typing, we removed samples based on the following exclusion
criteria: (i) unknown replicates (≥98.9% genetically identical)
that we were able to confirm; (ii) unknown replicates that we
were not able to confirm through discussions with study investi-
gators; (iii) samples with call rates ,95% after a second attempt;
(iv) samples with ≤5% African ancestry and (v) samples with
,15% mean heterozygosity of SNPs on the X chromosome
and/or similar mean allele intensities of SNPs on the X and Y
chromosomes (these are likely to be males). In the analysis, we
removed SNPs with ,95% call rates or MAFs ,1%. To
assess genotyping reproducibility, we included replicate
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samples, eliminating SNPs with genotyping concordance rates
,98% based on the replicates. The final analysis dataset
included 1 043 036 SNPs genotyped with an average SNP call
rate of 99.7% and average sample call rate of 99.8%. Imputation:
in order to generate a dataset suitable for fine-mapping, we
carried out genome-wide imputation using the software
MACH. Phased haplotype data from the founders of the CEU
and YRI HapMap Phase 2 samples were used to infer LD patterns
in order to impute un-genotyped markers. The r2 metric, defined
as the observed variance divided by the expected variance, pro-
vides a measure of the quality of the imputation at any SNP, and
was used as a threshold in determining which SNPs to filter from
analysis (r2 , 0.3). Phenotype Definition: the definition of
menopause was defined in the same manner as in the Multiethnic
Cohort Study (see the following section). Population Stratifica-
tion Correction: we used PCs analysis to estimate global ancestry
among the 5761 individuals, using 2546 ancestry informative
markers. To address the potential for confounding by genetic an-
cestry, we adjusted for global ancestry in all analyses.
The MEC is a prospective cohort study of 215 000 men and
women in Hawaii and Los Angeles between the ages of 45 and
75 years at baseline (1993–1996) (71). Through December, 31
2007, a nested breast cancer case–control study in the MEC
included 556 African-American cases (544 invasive and 12 in
situ) and 1003 African-American controls. An additional 178
African-American breast cancer cases (ages: 50–84 years) diag-
nosed between June 1, 2006 and December 31, 2007 in Los
Angeles County (but outside of the MEC) were combined with
the MEC samples in the analysis. Genomic DNA was extracted
for all samples using the QIAamp Blood Mini Kit (Qiagen, Val-
encia, CA, USA). Genotyping and Quality control: the genotyp-
ing and quality control procedures were identical to those used
for CBCS. Imputation: the imputation procedures were identical
to those used for CBCS. Phenotype Definition: age at last men-
strual period cannot be used to uniformly estimate age at meno-
pause because women who use sequential EPRT often continue
to have monthly menstrual periods, irrespective of their ovarian
function, and women on estrogen replacement therapy and con-
tinuous combined replacement therapy can rarely distinguish
breakthrough bleeding from ovarian function-determined
menses. Hence, for a woman taking HRT before her reported
age at last menstrual period, we set her age of menopause as
the year in which she began HRT use (excluding use of progestin
alone), with the rationale that HRT use was started because of
menopausal symptoms. Population Stratification Correction:
the method for population stratification correction was identical
to those used for CBCS.
Meta-analysis
We performed additional quality control on all genotyped and
imputed SNPs in each cohort by removing SNPs in each
cohort if they had ,1% MAF, they had fewer than five copies
of minor alleles, they were genotyped in fewer than 100 partici-
pants, or they had a quality score of ,0.3 if they were imputed. In
total, we have 3 252 746 SNPs that were found in at least one
cohort available for analyses. In all cohorts, linear regression
models were used to assess the association between each
SNP and age at menopause. An additive genetic model was
assumed using either genotyped SNPs or imputed SNP
dosages. Global ancestry was adjusted by incorporating the
first 10 PCs for each individual as covariates in the regression
models. In GENOA and MESA family, additional covariates
were included in the models to account for family structure in
the cohort. In WHI and CHS, clinical sites were included as a
covariate to correct for any geographical or socio-economical
differences. Meta-analyses on the linear regression results
were conducted using the Meta Analysis Helper (72). The
genomic control correction was turned on and the analysis was
based on effect sizes and their standard errors (SCHEME
STDERR). Results for SNPs found in only one cohort or
,1000 total participants were discarded.
We first performed a genome-wide discovery but no statistic-
ally significant associations were detected. To replicate previous
findings, we compiled a list of SNPs previously associated with
age at menopause in women with European ancestry. These
SNPs included 15 SNPs discovered in GWAS with P-values
,1027 (distributed across five loci), nine SNPs with P-values
between 1024 and 1027 (distributed across nine loci), 17 SNPs
discovered by a GWAS meta-analysis (distributed across 17
loci, of which 16 were novel) and seven SNPs implicated in can-
didate gene studies (distributed across six loci) (17–19,27–33).
The LD relationships among the SNPs in HapMap CEU in each
region were carefully examined to determine the effective
number of tests. Each region was tested at an a-level of 0.05.
We examined each region further by defining a LD block for
each region using the HapMap CEU population. Each LD
block was defined as the largest block within 500 kb of the
index SNPs on which the LD between the SNPs at both ends of
the block and the index SNPs have r2 ≥ 0.5. The LD relation-
ships among the SNPs on the same LD block were investigated
and only one SNP from high LD pairs (r2 ≥ 0.8) was kept.
For index SNPs that replicated successfully, we sought to
fine-map the signal by comparing the difference in LD structures
between HapMap CEU and YRI samples. Graphs depicting the
relationships between SNPs on the same LD block were created
using LocusZoom (73). We also searched for possible secondary
signals in the LD block.
In the event that the index SNP did not replicate, we identified
a list of SNPs with at least r2 ≥ 0.8 with the index SNPs in
HapMap CEU population using the Genome Variation Server
(http://gversusgs.washington.edu/GVS). We performed meta-
analyses for all of them to confirm that they had similar
P-values. We then assessed whether there was any signal on
the LD block by examining the SNPs on the block using a con-
servative Bonferroni correction based on the number of SNPs
tested. When a secondary signal was found, we performed con-
ditional analyses in each cohort with both the index SNP and the
newly identified SNP in the model. Using the results from these
conditional analyses, we performed a conditional meta-analysis
to confirm the existence of a secondary signal.
We determined the likely function of the SNPs we investi-
gated by utilizing the results from the Encyclopedia of DNA Ele-
ments Project (ENCODE) (74). In particular, we used the
information from the ENCODE Integrated Regulation and
ENCODE Chromatin State Segmentation by HMM from
Broad Institute, MIT and MGM tracks from the UCSC
Genome Browser (39). The ENCODE Integrated Regulation
track consists of information from the following source: tran-
scription levels assayed by RNA-seq on six-cell lines, enhancer-
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and promoter-associated histone mark (H3K4Me1) on eight-cell
lines, enhancer- andpromoter-associatedhistone mark (H3K27Ac)
on eight-cell lines, promoter-associated histone mark (H3K4Me3)
on nine-cell lines, digital DNaseI hypersensitivity clusters and tran-
scription factor ChiP-seq data.
Power calculations were performed using Quanto (version
1.2.4) using the gene-only model with a continuous trait pheno-
type and unrelated individuals (75). For the age at menopause,
we assumed a population mean of 50 years with a standard devi-
ation of 5.7.
The summary-level P-values for the current study can be
found in Supplementary Material, Table S5.
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